copd and asthma update
TRANSCRIPT
![Page 1: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/1.jpg)
Asthma and COPD
How can you make a difference?
![Page 2: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/2.jpg)
Disclosures
• Jo Congleton
• Consultant in Integrated Respiratory Care BSUH/SCFT
• Over the past few years I have given presentations at meetings and run educational training sessions for AstraZeneca and Boehringer Ingelheim
![Page 3: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/3.jpg)
Overview
• What is asthma?• Current themes in treatment
• What is COPD?• Current themes in treatment
• Non-pharmacological treatments
• How can you contribute to management?
![Page 4: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/4.jpg)
Medications Cost June 2012
Of the top 5 costliest drugs to the NHS, ALL are respiratory inhalers
• 5. Seretide 125 evohaler - £81 million/yr
• 4. Seretide 500 accuhaler - £85 million/yr
• 3. Symbicort 200 - £90 million/yr
• 2. Tiotropium - £120 million/yr
• 1. Seretide 250 evohaler - £180 million/yr
![Page 5: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/5.jpg)
Airways narrowing due to
bronchoconstriction and
inflammation; duration and
severity are risk factors for
development of airway
remodelling and COPD
Airways collapse due to
destruction of alveolar walls
– may lead to bullae
Airways narrowing due to
Chronic irritation of the bronchi causing
inflammation and changes to the mucociliary
escalator; often results in chronic cough
Large airway
inflammation
Small
airwaysEmphysema
Fibrosis
![Page 6: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/6.jpg)
Definition of COPD
COPD is predominantly caused by smoking and is characterised by
airflow obstruction that is not fully reversible
The airflow obstruction does not change markedly over several
months but is usually progressive in the long term
Exacerbations often occur, when there is a rapid and sustained
worsening of the patient’s symptoms beyond normal day-to-day
variations
NICE 2010
![Page 7: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/7.jpg)
Definition of Asthma
• Asthma is a chronic inflammatory condition characterised by variable and reversible airway obstruction
• Eosinophilic bronchitis
![Page 8: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/8.jpg)
Airways narrowing due to
bronchoconstriction and
inflammation; duration and
severity are risk factors for
development of airway
remodelling and COPD
Airways collapse due to
destruction of alveolar walls
– may lead to bullae
Airways narrowing due to
Chronic irritation of the bronchi causing
inflammation and changes to the mucociliary
escalator; often results in chronic cough
Large airway
inflammation
Small
airwaysEmphysema
Fibrosis
![Page 9: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/9.jpg)
DiagnosisPatients over 35
Smokers or ex-smokers
With any of the following:
exertional breathlessness
chronic cough
regular sputum production,
frequent winter ‘bronchitis’
wheeze
C
O
P
D
NICE COPD Guidelines 2010
![Page 10: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/10.jpg)
![Page 11: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/11.jpg)
![Page 12: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/12.jpg)
Diagnosis
Patients over 35
And no clinical features of asthma
Smokers or ex-smokers
With any of the following:
exertional breathlessness
chronic cough
regular sputum production,
frequent winter ‘bronchitis’
wheeze
C
O
P
D
NICE COPD Guidelines 2010
![Page 13: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/13.jpg)
• Wheezy Child
• DV PEFR chart
• Day to day variation
• b2 reversibility
• Steroid reversibility
• Atopy, Family History
SMOKERS CAN HAVE ASTHMA
• Onset 35- 55yrs
• Flat PEFR chart
• Constant symptoms
• Progressive SOB
• Little / no reversibility
• Significant smoking history
ATOPICS CAN HAVE COPD
![Page 14: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/14.jpg)
Does my patient have asthma or COPD?
Asthma COPD Overlap Syndrome? (ACOS)
• Many patients have features of asthma and COPD
• Older age group• Childhood asthma
• Significant smoking history
![Page 15: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/15.jpg)
Other diagnoses to consider
• Bronchiectasis
• ILD
• Dysfunctional Breathing/Vocal cord dysfunction
• Heart Failure
![Page 16: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/16.jpg)
Case VK
►68 year man
►Cough and SOB
►Cough 18 years, worse recently, egg cup of green sputum per day
►Breathlessness varies day to day
►Even a good day ex tol 30 yds
►Smoking History: 30 pk yrs, nil for 20 yrs
![Page 17: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/17.jpg)
CASE VK
• Treatment had been escalated
• Now on ‘triple thereapy’
• ICS component high dose
• No significant response to treatment
![Page 18: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/18.jpg)
![Page 19: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/19.jpg)
Asthma Management
• New BTS/SIGN guideliines
![Page 20: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/20.jpg)
Inhaled steroid use and Asthma Death
0
0.5
1
1.5
2
2.5
0 1 2 3 4 5 6 7 8 9 10 11 12
No. of canisters of inhaled
corticosteroids per year
RR Death fromAsthma
![Page 21: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/21.jpg)
Moving up and moving down
Adapted from British guideline on the management of asthma. 2016. Available from: https://www.brit-thoracic.org.uk/document-library/clinical-
information/asthma/btssign-asthma-guideline-quick-reference-guide-2016/ (accessed Oct 2016)
![Page 22: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/22.jpg)
• Initial add on therapy:• LABA plus low dose ICS – usually combination
• Consider maintenance and reliever therapy
• Additional add on therapies• Stop LABA and move to medium dose ICS
• Continue LABA, move to medium dose ICS
• Continue LABA/ICS and trial LTRA
• Continue LABA/ICS and trial SR theophylline
• Continue LABA/ICS and trial LAMA (unlicensed)
Adapted from British guideline on the management of asthma. 2016. Available from: https://www.brit-thoracic.org.uk/document-library/clinical-
information/asthma/btssign-asthma-guideline-quick-reference-guide-2016/ (accessed Oct 2016)
Consider moving up therapy if using 3 or more doses
of rescue β2 per week
![Page 23: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/23.jpg)
ICS Doses
• Low: Beclometasone 100mcg 2puffs bd
• Medium: Beclometasone 200mcg 2 puffs bd
• High Dose: Beclometasone 200mcg 4 puffs bd
Adapted from British guideline on the management of asthma. 2016. Available from: https://www.brit-thoracic.org.uk/document-library/clinical-
information/asthma/btssign-asthma-guideline-quick-reference-guide-2016/ (accessed Oct 2016)
![Page 24: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/24.jpg)
High dose therapies
• High dose ICS
• Addition of a 4th drug:• LTRA
• SR theophylline
• Beta agonist tablet
• LAMA
• REFER PATIENT FOR SPECIALIST CARE
Adapted from British guideline on the management of asthma. 2016. Available from: https://www.brit-thoracic.org.uk/document-
library/clinical-information/asthma/btssign-asthma-guideline-quick-reference-guide-2016/ (accessed Oct 2016)
![Page 25: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/25.jpg)
COPD Management
• Aim of treatment:
to relieve symptoms
reduce the risk of exacerbations
• Reduce risk of death
![Page 26: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/26.jpg)
QoF COPD Cases: B+H CCG (predicted 10,711)
3400
3500
3600
3700
3800
3900
4000
COPD
2011/12
2012/13
2013/14
2014/15
![Page 27: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/27.jpg)
Private and confidential
27
![Page 28: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/28.jpg)
Case FindingPatients over 35
Smokers or ex-smokers
With any of the following:
exertional breathlessness
chronic cough
regular sputum production,
frequent winter ‘bronchitis’
wheeze
C
O
P
D
NICE COPD Guidelines 2010
![Page 29: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/29.jpg)
COPD Management
• Relieve Symptoms
• Reduce Risk of Exacerbations
• Reduce risk of death
• Bronchodilators
• Pulmonary Rehabilitation
• LABA/ICS
• Bronchodilators
• Pulmonary Rehabilitation
• Smoking Cessation
• Smoking Cessation
• LTOT
![Page 30: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/30.jpg)
Risk Symptoms Exacerbations
High risk, less symptoms
ICS/LABA or LAMA
High risk, more symptoms
ICS/LABA
(triple therapy)
Low risk, less symptoms
SABA or SAMA
(LABA or LAMA)
Low risk, more symptoms
LAMA or LABA
(LAMA + LABA)
30
Exacerbator
2 or more per
year
Non-exacerbator
0 or 1 per year
mMRC <2 mMRC 2 or more
AFO: FEV1
< 50% pred
AFO: FEV1
> 50% pred
mMRC2 = MRC 3 Walks slower than most people on the level, stops after a
mile or so, or stops after 15 minutes walking at own pace
![Page 31: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/31.jpg)
Triple Therapy
£35,000-£187,000
LABA
£8,000/QALY
LAMA
£7,000/QALY
Pulmonary Rehabilitation
£2,000-8,000/QALY
Stop Smoking Support with pharmacotherapy £2,000/QALY
Flu vaccination £?1,000/QALY in “at risk” population
The Value Pyramid
![Page 32: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/32.jpg)
![Page 33: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/33.jpg)
![Page 34: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/34.jpg)
VBAT
• Very Brief Advice Training
• http://www.ncsct.co.uk/publication_very-brief-advice.php
![Page 35: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/35.jpg)
Triple Therapy
£35,000-£187,000
LABA
£8,000/QALY
LAMA
£7,000/QALY
Pulmonary Rehabilitation
£2,000-8,000/QALY
Stop Smoking Support with pharmacotherapy £2,000/QALY
Flu vaccination £?1,000/QALY in “at risk” population
The Value Pyramid
![Page 36: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/36.jpg)
Pulmonary RehabilitationA structured programme combining:
• supervised exercise training (the core of PR)
• a comprehensive educational programme
• psychosocial support ATS/ERS Guidelines 2006
ACCP/ AACVPR Evidence-Based Clinical Practice Guidelines 2007
![Page 37: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/37.jpg)
Evidence for Pulmonary Rehabilitation
Improvements in multiple outcomes of
considerable importance to the patient:
Dyspnoea
↓SOB for a given amount or intensity of activity
Exercise capacity
Health Related Quality of Life
up to 9/12 post PR
NICE Guidelines 2004,2011; ATS/ERS Guidelines 2006
Lacasse 1997, 2004; Cambach 2002; Griffiths 2003
ACCP/ AACVPR Evidence-Based Clinical Practice Guidelines 2007
![Page 38: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/38.jpg)
Medicines Optimisation:Opportunities
• Reduce ICS burden
• Rationalising inhaled therapies and reducing cost
• Referring for PR early to defer need for higher level meds
• Joint working: local pharmacists, community teams, primary care
• Joint formularies
• Clear consistent messages
Value Pyramid
![Page 39: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/39.jpg)
Seretide Accuhaler ®(Salmeterol & Fluticasone propionate)
Symbicort Turbohaler ®(Formoterol & Budesonide)
DuoResp Spiromax ®(Formoterol & Budesonide)
Symbicort ® – Formoterol& Budesonide))
Relvar Ellipta ®▼ – (vilanterol & Fluticasone Furoate)
Long Acting Bronchodilators and
Inhaled Corticosteroids
MDINEXThaler
AirFluSal Forspiro ®(Salmeterol & Fluticasone propionate)
Fostair ® – (Formoterol & Beclometasone)
![Page 40: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/40.jpg)
ICS and Pneumonia
• All studies have shown an increased risk of community acquired pneumonia with high dose ICS
• Aim to keep ICS burden as low as possible
![Page 41: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/41.jpg)
Anoro Ellipta ®▼(Vilanterol & Umeclidinium)
Duaklir Genuair ®▼(Formoterol & Aclidinium)
Ultibro Breezhaler ®▼(Indacaterol & Glycopyrronium)
Long acting bronchodilators and long acting muscarinics
Spiolto Respimat ®▼(Oldaterol/ Tiotropium)
![Page 42: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/42.jpg)
Risk Symptoms Exacerbations
High risk, less symptoms
ICS/LABA or LAMA
High risk, more symptoms
ICS/LABA
(triple therapy)
Low risk, less symptoms
SABA or SAMA
(LABA or LAMA)
Low risk, more symptoms
LAMA or LABA
(LAMA + LABA)
42
Exacerbator
2 or more per
year
Non-exacerbator
0 or 1 per year
mMRC <2 mMRC 2 or more
AFO: FEV1
< 50% pred
AFO: FEV1
> 50% pred
mMRC2 = MRC 3 Walks slower than most people on the level, stops after a
mile or so, or stops after 15 minutes walking at own pace
![Page 43: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/43.jpg)
Does my patient have asthma or COPD?orWhat is this Asthma COPD Overlap Syndrome? (ACOS)
• Many patients have features of asthma and COPD
• Older age group• Childhood asthma
• Significant smoking history
• Main therapeutic difference is to use LAMA earlier (than if pure asthma)
• And to use lower doses of ICS (than if pure COPD)
![Page 44: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/44.jpg)
Asthma COPD and Asthma-COPD Overlap Syndrome (ACOS) 2014 – www.ginasthma.org
![Page 45: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/45.jpg)
wp-content/uploads/20
15/03/Drugs-and-Devices-Aprilm-
2015.pdf45
![Page 46: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/46.jpg)
46
![Page 47: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/47.jpg)
The correct inhaler device….
• …Is the one that the patient is able to use and will use
• There is no place for an ICS containing mdi without a spacing device
![Page 48: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/48.jpg)
Relative lung dose, shown as maximal plasma salbutamol concentration (Cmax), from the early lung absorption
profile over the first 20 minutes following inhalation of a 1200 μg nominal dose of salbutamol.
STEPHEN J FOWLER, and BRIAN J LIPWORTH Thorax 2000;55:345
Copyright © BMJ Publishing Group Ltd & British Thoracic Society. All rights reserved.
![Page 49: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/49.jpg)
Tips for pharmacists
• If dispensing an ICS or ICS combination always ask if patient has and is using a spacing device
• Alert if dispensing frequent SABA prescriptions (especially asthma)
• If dispensing high dose ICS flag up to GP/patient
• If you know/think the patient has asthma are you dispensing 1 device per month?
• Always ask about inhaler technique
• Consider promoting non-pharmacological treatments• SSS• PR• Self Excerise• Influenza VAc
![Page 50: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/50.jpg)
![Page 51: COPD and Asthma Update](https://reader031.vdocuments.net/reader031/viewer/2022012505/617f8775acb8f67cdd34893e/html5/thumbnails/51.jpg)